

ABSTRACT

The present invention refers to steroid derivatives for use as medicaments.

More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5- pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect.

Examples of such steroid derivatives are -5-androstene-17 -ol, androstane-17 -ol-pregnane-17 -ol or pregnane-17 -ol derivatives. In a further aspect, the invention 10 relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3 $\beta$ ,17 -dio l or androstane-3 $\beta$  -diol, an enzyme and a sulfotransferase to provide 5-androstene-17 -ol-3 $\beta$ -sulfate or corresponding andros tane derivative (17 -AEDS or 17-AADS); and mixing the 17 -AEDS or 17 -AADS so produced with a 15 suitable carrier; whereby a medicament which is capable of acting as a ligand to peroxisome proliferators-activated receptor- (PPAR ) is produced.